During a live event, Danielle M. Brander, MD, discussed use of zanubrutinib in high-risk chronic lymphocytic leukemia.

AstraZeneca’s share price has fallen a lot from its September high, but this could mean a tremendous opportunity for me to ...

The EC has granted approval for a fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) plus venetoclax.